(Q46188537)

English

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

medulloblastoma

0 references

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Deanna Mitchell

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Genevieve Bergendahl

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

William Ferguson

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

William Roberts

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Timothy Higgins

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Takamaru Ashikaga

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Mike DeSarno

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Joel Kaplan

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Jacqueline Kraveka

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Don Eslin

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Alyssa Vander Werff

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Gina K Hanna

12

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Giselle L Saulnier Sholler

13

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

publication date

31 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Pediatric Blood Cancer

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

63

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

39-46

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

A population-based study of neuroblastoma incidence, survival, and mortality in North America.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Neuroblastoma: biology, prognosis, and treatment

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Update on new treatments and developments in childhood brain tumors.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

New microtubular agents in pediatric oncology

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Taxanes in paediatric oncology: and now?

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Ethanol pharmacokinetics in neonates and infants

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25687

21 January 2018

Identifiers

10.1002/PBC.25687

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/26235333

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46188537&oldid=2099023500"